Denali Therapeutics Inc (DNLI) - Total Liabilities
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has total liabilities worth $129.42 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Denali Therapeutics Inc (DNLI) cash conversion ratio to assess how effectively this company generates cash.
Denali Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Denali Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check DNLI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Denali Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Denali Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
China | CN¥2.39 Billion |
|
Diodes Incorporated
NASDAQ:DIOD
|
USA | $509.69 Million |
|
Hangzhou Cable
SHG:603618
|
China | CN¥7.46 Billion |
|
Zuger Kantonalbank
SW:ZUGER
|
Switzerland | CHF17.65 Billion |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
China | CN¥12.87 Billion |
|
Privia Health Group Inc
NASDAQ:PRVA
|
USA | $578.43 Million |
|
CoCreation Grass Co Ltd
SHG:605099
|
China | CN¥837.51 Million |
|
P/f Bakkafrost
OL:BAKKA
|
Norway | Nkr7.91 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Denali Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DNLI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Denali Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Denali Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of Denali Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $144.50 Million | +17.51% |
| 2023-12-31 | $122.96 Million | -70.57% |
| 2022-12-31 | $417.81 Million | -5.44% |
| 2021-12-31 | $441.87 Million | -2.62% |
| 2020-12-31 | $453.75 Million | +186.56% |
| 2019-12-31 | $158.34 Million | +37.52% |
| 2018-12-31 | $115.14 Million | +450.25% |
| 2017-12-31 | $20.93 Million | +26.45% |
| 2016-12-31 | $16.55 Million | -68.37% |
| 2015-12-31 | $52.32 Million | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-… Read more